LabenzC, KremerWM, SchattenbergJM, . Clinical frailty scale for risk stratification in patients with SARS-CoV-2 infection. J Investig Med2020;68:1199–202.doi:10.1136/jim-2020-001410http://www.ncbi.nlm.nih.gov/pubmed/32641351
2.
MuscedereJ, WatersB, VaramballyA, . The impact of frailty on intensive care unit outcomes: a systematic review and meta-analysis. Intensive Care Med2017;43:1105–22.doi:10.1007/s00134-017-4867-0http://www.ncbi.nlm.nih.gov/pubmed/28676896
3.
WangL, HeW, YuX, . Coronavirus disease 2019 in elderly patients: characteristics and prognostic factors based on 4-week follow-up. J Infect2020;80:639–45.doi:10.1016/j.jinf.2020.03.019http://www.ncbi.nlm.nih.gov/pubmed/32240670
4.
HewittJ, CarterB, Vilches-MoragaA, . The effect of frailty on survival in patients with COVID-19 (cope): a multicentre, European, observational cohort study. Lancet Public Health2020. doi:doi:10.1016/S2468-2667(20)30146-8. [Epub ahead of print: 30 Jun 2020].http://www.ncbi.nlm.nih.gov/pubmed/32619408
5.
AldridgeRW, LewerD, KatikireddiSV, . Black, Asian and minority ethnic groups in England are at increased risk of death from COVID-19: indirect standardisation of NHS mortality data. Wellcome Open Res2020;5:88.doi:10.12688/wellcomeopenres.15922.2http://www.ncbi.nlm.nih.gov/pubmed/32613083
6.
IaccarinoG, GrassiG, BorghiC, . Age and multimorbidity predict death among COVID-19 patients: results of the SARS-RAS study of the Italian Society of hypertension. Hypertension2020;76:366–72.doi:10.1161/HYPERTENSIONAHA.120.15324http://www.ncbi.nlm.nih.gov/pubmed/32564693
7.
YangJ, ZhengY, GouX, . Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. Int J Infect Dis2020;94:91–5.doi:10.1016/j.ijid.2020.03.017http://www.ncbi.nlm.nih.gov/pubmed/32173574
8.
WangB, LiR, LuZ, . Does comorbidity increase the risk of patients with COVID-19: evidence from meta-analysis. Aging2020;12:6049–57.doi:10.18632/aging.103000http://www.ncbi.nlm.nih.gov/pubmed/32267833
9.
FlickH, ArnsBM, BolitschekJ, . Management of patients with SARS-CoV-2 infections and of patients with chronic lung diseases during the COVID-19 pandemic (as of 9 may 2020): statement of the Austrian Society of Pneumology (ASP). Wien Klin Wochenschr2020:1–22.
10.
CenY, ChenX, ShenY, . Risk factors for disease progression in patients with mild to moderate coronavirus disease 2019-a multi-centre observational study. Clin Microbiol Infect2020. doi:doi:10.1016/j.cmi.2020.05.041. [Epub ahead of print: 09 Jun 2020].http://www.ncbi.nlm.nih.gov/pubmed/32526275
11.
ZhangJJY, LeeKS, AngLW, . Risk factors of severe disease and efficacy of treatment in patients infected with COVID-19: a systematic review, meta-analysis and meta-regression analysis. Clin Infect Dis2020. doi:doi:10.1093/cid/ciaa576. [Epub ahead of print: 14 May 2020].http://www.ncbi.nlm.nih.gov/pubmed/32407459
